Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions, Inc. (NYSE: EBS) is a global life sciences company dedicated to protecting and enhancing life. With a mission to secure public health, Emergent develops, manufactures, and distributes a broad portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company is committed to safeguarding lives and aims to protect and enhance 50 million lives with its products by 2025.
Headquartered in Gaithersburg, Maryland, Emergent operates through three primary segments: Commercial, Products, and Services. The Commercial segment, which generates the majority of the company's revenue, includes key products such as NARCAN® Nasal Spray—a life-saving medication for opioid overdoses. NARCAN® has become widely accessible in pharmacies, grocery stores, and online retailers, significantly increasing public availability since its over-the-counter approval by the FDA in March 2023.
Emergent is also known for its role in developing and manufacturing vaccines and therapeutics, particularly for governments and healthcare providers. The company's Baltimore Bayview manufacturing facility recently received a “No Action Indicated” status from the FDA, confirming its compliance with good manufacturing practices. This recognition underscores Emergent's dedication to quality and compliance in its manufacturing processes.
Financially, Emergent is focused on stabilizing its operations and strengthening its balance sheet. The recent restructuring plan aims to streamline operations, close certain manufacturing facilities, and reduce workforce by 300 employees, resulting in annualized savings of approximately $80 million. Despite these changes, Emergent remains dedicated to its core business areas and continues to offer integrated contract development and manufacturing services to pharmaceutical and biotechnology customers.
Key recent developments include the extension of NARCAN® Nasal Spray's shelf life from 36 to 48 months and its widespread distribution across the U.S. and Canada. Emergent is also actively working with partners like the National Safety Council to educate businesses and the public about opioid overdose prevention and response.
Emergent is committed to its long-term vision of protecting and enhancing 1 billion lives by 2030. The company continues to innovate and expand its product offerings while maintaining a strong focus on public health and safety.
Emergent BioSolutions (NYSE:EBS) has secured an indefinite-delivery, indefinite-quantity contract valued at up to $379.6 million to supply the Reactive Skin Decontamination Lotion Kit (RSDL®) to the U.S. military. The contract includes a base year starting December 2022 and four optional annual renewals. RSDL® has been utilized by the U.S. for 13 years and is designed to neutralize chemical warfare agents. Emergent emphasizes its commitment to public health and military preparedness through this contract.
Emergent BioSolutions Inc. (NYSE:EBS) has received FDA acceptance for its supplemental New Drug Application (sNDA) for NARCAN® (naloxone HCl) Nasal Spray as an over-the-counter (OTC) emergency treatment for opioid overdose, marking a historic first. The FDA has granted Priority Review, with a decision expected by March 29, 2023. The move aims to enhance access to NARCAN amid a rising opioid crisis, which saw over 71,000 fatalities from opioids in 2021 alone. Emergent plans to leverage five years of post-marketing data and Human Factors studies to support the application.
Emergent BioSolutions has announced a research award from the U.S. Department of Defense to evaluate the efficacy of its single-dose chikungunya virus vaccine candidate. The collaboration involves the Armed Forces Research Institute of Medical Sciences to conduct a Phase 3b clinical study assessing the vaccine's effectiveness in areas with active chikungunya transmission. The initiative is backed by a $10 million budget for planning and clinical phases, supporting the aim to combat chikungunya, a significant public health threat.
Emergent BioSolutions (NYSE: EBS) reported Q3 2022 financial results, revealing total revenues of $240 million, a decline of 27% compared to Q3 2021. The company faced a net loss of $75.7 million and adjusted EBITDA of $(15.2 million. Product sales fell 31% year-over-year, driven by decreased sales of nasal naloxone and ACAM2000. Despite challenges, the acquisition of TEMBEXA and ongoing clinical trials for vaccine candidates show potential for future growth. The revised 2022 financial outlook projects total revenues between $1.05 billion and $1.1 billion.
Emergent BioSolutions (NYSE:EBS) announced positive Phase 2 results for its chikungunya virus vaccine candidate. The study included 60 healthy adults, showing that the vaccine was well-tolerated and immunogenic in both vaccine-naïve participants and those previously vaccinated against other alphavirus vaccines. Notably, the seroconversion rate was 100% in both groups. The findings were presented at the ASTMH annual meeting, highlighting the potential utility of the vaccine for U.S. military personnel facing heightened exposure risks. Currently, there are no approved vaccines for chikungunya disease.
Emergent BioSolutions (NYSE: EBS) has scheduled a conference call for November 8, 2022, at 5:00 PM ET to review its Q3 2022 financial results, recent business developments, and 2022 financial outlook. Investors can join via webcast or by phone after registering. A replay will be accessible on the company’s investor page. Emergent BioSolutions focuses on defending public health threats through vaccines and therapeutics and aims to enhance the lives of one billion people by 2030.
Emergent BioSolutions (NYSE: EBS) has successfully acquired exclusive worldwide rights to TEMBEXA® (brincidofovir) from Chimerix. The FDA-approved antiviral, indicated for smallpox treatment in all age groups, enhances Emergent's medical countermeasure portfolio. The acquisition follows regulatory approvals, including BARDA's consent for a $680 million contract covering up to 1.7 million treatment courses. Emergent's initial payment is $238 million, with additional milestone and royalty payments based on U.S. and international sales.
Emergent BioSolutions (NYSE: EBS) has commenced dosing the first participant in a Phase 1 clinical trial of EBS-LASV, a VSV-vectored vaccine aimed at combating Lassa virus infections. The study, co-funded by CEPI, will assess the vaccine's safety and immunogenicity in around 36 healthy adults in Ghana. Dr. Kelly Warfield emphasized the company's commitment to addressing public health threats, while CEPI highlighted the urgency of developing solutions against Lassa fever, which currently lacks approved vaccines or treatments.
Emergent BioSolutions (NYSE: EBS) announced participation in several investor conferences in August and September 2022. Key events include the 12th Annual Midwest IDEAS Investor Conference on August 24, a fireside chat at the Wells Fargo 2022 Healthcare Conference and Leveraged Finance Conference on September 8, and the Morgan Stanley 20th Annual Global Healthcare Conference from September 12-14. Webcast presentations will cover recent business developments and financial results, available live and on replay from the Emergent website.
Emergent BioSolutions (NYSE: EBS) reported Q2 2022 results with total revenues of $242.7 million, down 39% year-over-year. Net loss reached $56.4 million, marking a significant decline from the prior year's profit of $4.6 million. Adjusted EBITDA stood at $(28.8) million, down from $49.5 million. The company executed an agreement to acquire TEMBEXA and announced an FDA review of its anthrax vaccine. For 2022, total revenue guidance has been set at $1.15 to $1.25 billion, with CDMO revenues projected at $105 to $125 million.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
What is Emergent BioSolutions' core mission?
What are the main segments of Emergent BioSolutions?
What is NARCAN® Nasal Spray?
What recent compliance certification did Emergent receive?
What are Emergent's recent restructuring plans?
How is Emergent enhancing the availability of NARCAN® Nasal Spray?
What financial goals does Emergent have?
What is Emergent's vision for the future?
What services does Emergent offer to pharmaceutical and biotechnology customers?
How can stakeholders participate in Emergent's conference calls?
